NEW YORK (GenomeWeb) – LexaGene said today that it has raised about C$5.8 million ($4.6 million) in a bought deal stock offering to underwriters led by Canaccord Genuity.

Earlier this week the company announced a deal in which underwriters agreed to purchase a total of 4.4 million units of the company's stock at a price of C$1.15 per unit for aggregate gross proceeds to Lexagene of just over C$5.0 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.